OBJECTIVE: The aim of this study was to examine the effect of rapid tryptophan depletion (RTD) combined with a panicogenic challenge in patients with panic disorder who had responded to treatment with cognitive behavioural therapy (CBT). We hypothesised that RTD (compared with the control drink) would result in an increase in anxiety symptoms when provoked by a panicogenic challenge with the benzodiazepine antagonist, flumazenil. METHODS:Nine patients with panic disorder who had responded to CBT received atryptophan-free amino acid drink on one occasion and a control drink on the other in a double-blind crossover design. In addition, they received flumazenil and placebo infusions on each day. RESULTS: Our hypothesis regarding the effects of RTD was supported by findings of a significant interaction between RTD and flumazenil on measures from visual analogues scales (total) and the Spielberger State Anxiety inventory. A somewhat unexpected finding was that in this group of CBT responders, the panicogenic effect of flumazenil was not completely blocked by treatment. This meant that although four of the nine subjects (44%) reported a panicogenic effect of flumazenil on the RTD day, this was not significantly different from the rate of panic attacks in response to flumazenil on the control day. CONCLUSION: We suggest that the partial return of symptoms in response to flumazenil reflects a vulnerability to RTD in this group of panic disorder patients who had responded to treatment with CBT.
RCT Entities:
OBJECTIVE: The aim of this study was to examine the effect of rapid tryptophan depletion (RTD) combined with a panicogenic challenge in patients with panic disorder who had responded to treatment with cognitive behavioural therapy (CBT). We hypothesised that RTD (compared with the control drink) would result in an increase in anxiety symptoms when provoked by a panicogenic challenge with the benzodiazepine antagonist, flumazenil. METHODS: Nine patients with panic disorder who had responded to CBT received a tryptophan-free amino acid drink on one occasion and a control drink on the other in a double-blind crossover design. In addition, they received flumazenil and placebo infusions on each day. RESULTS: Our hypothesis regarding the effects of RTD was supported by findings of a significant interaction between RTD and flumazenil on measures from visual analogues scales (total) and the Spielberger State Anxiety inventory. A somewhat unexpected finding was that in this group of CBT responders, the panicogenic effect of flumazenil was not completely blocked by treatment. This meant that although four of the nine subjects (44%) reported a panicogenic effect of flumazenil on the RTD day, this was not significantly different from the rate of panic attacks in response to flumazenil on the control day. CONCLUSION: We suggest that the partial return of symptoms in response to flumazenil reflects a vulnerability to RTD in this group of panic disorderpatients who had responded to treatment with CBT.
Authors: Linda Booij; Willem Van der Does; Chawki Benkelfat; J Douglas Bremner; Philip J Cowen; Maurizio Fava; Christian Gillin; Marco Leyton; Polly Moore; Katharine A Smith; Willem A Van der Kloot Journal: Neuropsychopharmacology Date: 2002-11 Impact factor: 7.853
Authors: Alexander Neumeister; Xian-Zhang Hu; David A Luckenbaugh; Markus Schwarz; Allison C Nugent; Omer Bonne; Peter Herscovitch; David Goldman; Wayne C Drevets; Dennis S Charney Journal: Arch Gen Psychiatry Date: 2006-09
Authors: John P O'Reardon; Mohit P Chopra; Alexandra Bergan; Robert Gallop; Robert J DeRubeis; Paul Crits-Christoph Journal: Biol Psychiatry Date: 2004-05-01 Impact factor: 13.382
Authors: Sean David Hood; Amanda Norman; Dana Adelle Hince; Jan Krzysztof Melichar; Gary Kenneth Hulse Journal: Br J Clin Pharmacol Date: 2014-02 Impact factor: 4.335
Authors: Alessandro Colasanti; Gabriel Esquivel; Erik den Boer; Annerieke Horlings; Abdul Dandachi; Jeff L Oostwegel; Eva L van Donkelaar; Eric J Griez; Koen Schruers Journal: Psychopharmacology (Berl) Date: 2011-02-19 Impact factor: 4.530
Authors: Simone M E Schopman; Renske C Bosman; Anna D T Muntingh; Anton J L M van Balkom; Neeltje M Batelaan Journal: Transl Psychiatry Date: 2021-02-11 Impact factor: 6.222